Tiffany Yvonne Loh, MD
Micrographic Dermatologic Surgery (Mds) · San Jose
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 2
- 2 carriers
- Offices
- 3
Offices
3 locations · Sutter Bay Medical Foundation · 3,783 clinicians in this group
Hospitals listed: City of Hope Helford Clinical Research Hospital. That is not proof they admit you there this week.
Plans that list them
2 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Loh’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
2 of 2 plans
| Alignment Health Sutter Advantage +More (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A172346 · Current
Licensed to practise in California · since 2021 · expires 2027-04-30 · University of California, San Diego School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Original Medicare doctor bills
$226,504
Medicare paid this office $226,504 for 499 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Removal and microscopic exam of growth of head, neck, hands, feet, or genitals, 1-5 tissue blocks | 96 | $55,360 | $429 |
| Removal and microscopic exam of growth of head, neck, hands, feet, or genitals, each additional stage, 1-5 tissue blocks | 48 | $27,052 | $366 |
| Short return visit (20+ min) | 178 | $12,990 | $62 |
| Repair of wound of forehead, cheeks, chin, mouth, neck, underarms, genitals, hands, or feet by transferring skin, 10.0 sq cm or less | 18 | $11,773 | $620 |
| Full thickness skin graft to nose, ears, eyelids, or lips, 20.0 sq cm or less | 11 | $10,288 | $857 |
See all 24 services
| Removal and microscopic exam of growth of head, neck, hands, feet, or genitals, 1-5 tissue blocks | 96 | $55,360 | $429 |
| Removal and microscopic exam of growth of head, neck, hands, feet, or genitals, each additional stage, 1-5 tissue blocks | 48 | $27,052 | $366 |
| Short return visit (20+ min) | 178 | $12,990 | $62 |
| Repair of wound of forehead, cheeks, chin, mouth, neck, underarms, genitals, hands, or feet by transferring skin, 10.0 sq cm or less | 18 | $11,773 | $620 |
| Full thickness skin graft to nose, ears, eyelids, or lips, 20.0 sq cm or less | 11 | $10,288 | $857 |
| Repair of wound of eyelids, nose, ears, or lips by transferring skin, 10.0 sq cm or less | 15 | $9,213 | $614 |
| Biopsy of related skin growth, first growth | 95 | $7,456 | $68 |
| Removal and microscopic exam of growth of head, neck, hands, feet, or genitals, 1-5 tissue blocks | 25 | $5,749 | $180 |
| New patient visit (30+ min) | 65 | $3,834 | $59 |
| Short return visit (20+ min) | 69 | $3,778 | $52 |
| New patient visit (30+ min) | 44 | $3,508 | $80 |
| Biopsy of related skin growth, each additional growth | 36 | $3,009 | $42 |
| Complicated repair of wound of forehead, cheeks, chin, mouth, neck, underarms, genitals, hands, or feet, 2.6-7.5 cm | 14 | $2,898 | $193 |
| Complicated repair of wound of scalp, arms, or legs, 2.6-7.5 cm | 13 | $2,578 | $172 |
| Biopsy of related skin growth, first growth | 55 | $1,788 | $28 |
| Destruction of precancer skin growth, 1 growth | 48 | $1,718 | $31 |
| Destruction of skin growth, 1-14 growths | 20 | $1,654 | $75 |
| Destruction of precancer skin growth, 2-14 growths | 43 | $1,239 | $5 |
| Return visit (30+ min) | 12 | $1,211 | $81 |
| Destruction of precancer skin growth, 1 growth | 20 | $949 | $47 |
| Short return visit | 18 | $761 | $42 |
| Biopsy of related skin growth, each additional growth | 19 | $705 | $18 |
| New patient visit (15+ min) | 12 | $429 | $36 |
| Destruction of precancer skin growth, 2-14 growths | 18 | $139 | $2 |
Procedures Medicare counted
| Melanoma (skin cancer) excision | 235 | More than 98% of doctors who do this |
| Removal of nail tissue | 1-10 | None |
| Removal of skin cancer | 600 | More than 68% of doctors who do this |
| Removal of skin lesions | 1-10 | None |
| Skin biopsy | 25 | More than 65% of doctors who do this |
Who their Medicare patients are
499 Original Medicare patients in 2024. Average age 74 · Under 65 6% · 85 and older 12% · Women 55% · Also on Medicaid 20% · Health risk score 1.66. Sicker patients than 9 in 10 peers; the typical dermatology clinician is at 1.01.
Conditions among them: High blood pressure 75% · Cancer 34% · Diabetes 30% · Coronary heart disease 30% · Chronic kidney disease 24% · Depression 24% · COPD 16% · Atrial fibrillation 16% · Heart failure 14% · Stroke 9% · Dementia 8%.
The office billed $1,043,842, Medicare allowed $297,205 and paid $226,504; for 1,687 services of 60 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 499 | 1,687 | 74 | 1.66 | $1,043,842 | $226,504 |
| 2023 | 430 | 1,535 | 72 | 2.06 | $298,873 | $68,237 |
| 2022 | 137 | 244 | 73 | 1.89 | $103,189 | $22,707 |
| 2021 | 60 | 71 | 74 | 1.47 | $37,767 | $10,073 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 19 services
| New patient visit (30+ min) | 164 | $11,315 | $69 |
| Short return visit (20+ min) | 97 | $7,247 | $54 |
| Short return visit (20+ min) | 71 | $5,777 | $79 |
| Destruction of precancer skin growth, 1 growth | 54 | $3,520 | $48 |
| Biopsy of related skin growth, first growth | 36 | $3,207 | $89 |
| Biopsy of related skin growth, first growth | 93 | $2,877 | $26 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 22 | $2,451 | $111 |
| Biopsy of related skin growth, each additional growth | 18 | $2,043 | $46 |
| Punch biopsy, first skin growth | 46 | $1,853 | $39 |
| New patient visit (30+ min) | 19 | $1,826 | $96 |
| Biopsy of related skin growth, each additional growth | 36 | $1,757 | $18 |
| Destruction of skin growth, 1-14 growths | 19 | $1,644 | $61 |
| Destruction of precancer skin growth, 1 growth | 29 | $1,316 | $44 |
| Destruction of skin growth, 1-14 growths | 12 | $1,267 | $106 |
| Short return visit | 18 | $885 | $49 |
| Destruction of precancer skin growth, 2-14 growths | 28 | $845 | $6 |
| New patient visit (15+ min) | 20 | $783 | $39 |
| Short return visit | 19 | $578 | $29 |
| Destruction of precancer skin growth, 2-14 growths | 51 | $569 | $2 |
2022: 6 services
| Return visit (30+ min) | 53 | $5,230 | $97 |
| Complicated repair of wound of scalp, arms, or legs, 2.6-7.5 cm | 14 | $4,768 | $341 |
| New patient visit (30+ min) | 17 | $1,196 | $70 |
| Punch biopsy, first skin growth | 17 | $641 | $38 |
| New patient visit (15+ min) | 12 | $455 | $38 |
| Biopsy of related skin growth, first growth | 12 | $304 | $25 |
2021: 1 service
| Return visit (30+ min) | 41 | $4,713 | $112 |
Medicaid work
$550 in 2023
Medicaid paid $550 for 12 billed services this clinician did in 2023, up to 12 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| New patient visit (30+ min) | 12 | $550 |
| 2023 | 12 | 1 | 12 | $550 |
Drugs they prescribed that Part D paid
$3,511
Pharmacies billed $3,511 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
209 generic and 23 brand-name prescriptions · $3,511 in drug cost · 103 antibiotic prescriptions to 85 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Fluorouracil | 15 | $1,159 | $68 |
| Doxycycline Hyclate | 77 | $662 | $7 |
| Ketoconazole | 11 | $187 | $16 |
| Silver Sulfadiazine | 11 | $89 | $7 |
| Hydrocortisone | 12 | $84 | $5 |
See all 6 drugs
| Fluorouracil | 15 | $1,159 | $68 |
| Doxycycline Hyclate | 77 | $662 | $7 |
| Ketoconazole | 11 | $187 | $16 |
| Silver Sulfadiazine | 11 | $89 | $7 |
| Hydrocortisone | 12 | $84 | $5 |
| Triamcinolone Acetonide | 16 | $83 | $5 |
Year by year
| 2024 | 232 | 160 | None | 10% | $3,511 |
| 2023 | 175 | 106 | 0% (0) | None | $10,843 |
| 2022 | 249 | 224 | None | 0% | $3,069 |
| 2021 | 222 | 102 | None | 9% | $98,621 |
| 2020 | 270 | 103 | 0% (0) | 17% | $225,203 |
| 2019 | 214 | 100 | 0% (0) | 11% | $88,347 |
| 2018 | 75 | 50 | None | None | $3,750 |
| 2017 | 56 | 30 | None | None | $8,866 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 7 drugs
| Clobetasol Propionate | 25 | $4,245 | $170 |
| Fluorouracil | 11 | $1,259 | $114 |
| Clindamycin Phosphate | 13 | $613 | $47 |
| Triamcinolone Acetonide | 42 | $453 | $11 |
| Ketoconazole | 15 | $342 | $23 |
| Doxycycline Hyclate | 15 | $166 | $11 |
| Hydrocortisone | 17 | $134 | $8 |
2022: 2 drugs
| Doxycycline Hyclate | 200 | $1,889 | $9 |
| Cephalexin | 13 | $113 | $9 |
2021: 6 drugs
| Fluorouracil | 15 | $1,387 | $92 |
| Clindamycin Phosphate | 12 | $786 | $66 |
| Clobetasol Propionate | 17 | $658 | $39 |
| Fluocinonide | 11 | $486 | $44 |
| Triamcinolone Acetonide | 25 | $473 | $19 |
| Doxycycline Hyclate | 29 | $405 | $14 |
2020: 7 drugs
| Dupixent | 14 | $43,068 | $3,076 |
| Fluorouracil | 16 | $2,019 | $126 |
| Clindamycin Phosphate | 17 | $762 | $45 |
| Clobetasol Propionate | 14 | $575 | $41 |
| Triamcinolone Acetonide | 28 | $367 | $13 |
| Ketoconazole | 17 | $279 | $16 |
| Prednisone | 11 | $196 | $18 |
2019: 6 drugs
| Fluorouracil | 25 | $2,363 | $95 |
| Fluocinonide | 14 | $1,905 | $136 |
| Triamcinolone Acetonide | 40 | $579 | $14 |
| Ketoconazole | 20 | $456 | $23 |
| Gabapentin | 13 | $125 | $10 |
| Hydrocortisone | 11 | $73 | $7 |
2018: 1 drug
| Fluorouracil | 16 | $1,429 | $89 |
Money from drug and device companies
$1,011 in 2025
| 2025 | 9 | 40 | None | $1,011 |
| 2024 | 3 | 5 | None | $132 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Janssen Biotech | Tremfya | $220 | 9 payments
|
| Lilly USA | Taltz | $163 | 6 payments
|
| Novartis Pharmaceuticals | Cosentyx | $154 | 6 payments
|
| Regeneron Healthcare Solutions | Dupixent | $138 | 6 payments
|
| Genzyme | Dupixent | $135 | 4 payments
|
| Abbvie | Rinvoq | $63 | 3 payments
|
See all 40 published payments
| Incyte | Meals · 2025-12-22 | Opzelura | $20 |
| Genzyme | Meals · 2025-12-22 | Dupixent | $37 |
| Janssen Biotech | Meals · 2025-12-15 | Tremfya | $34 |
| Incyte | Meals · 2025-12-11 | Opzelura | $17 |
| Novartis Pharmaceuticals | Meals · 2025-12-01 | Cosentyx | $20 |
| Ortho Dermatologics a division of Bausch Health US | Meals · 2025-11-24 | Cabtreo | $22 |
| Regeneron Healthcare Solutions | Meals · 2025-11-18 | Dupixent | $27 |
| Genzyme | Meals · 2025-11-12 | Dupixent | $35 |
| Abbvie | Meals · 2025-11-06 | Rinvoq | $16 |
| Ucb | Meals · 2025-11-04 | Bimzelx | $30 |
| Janssen Biotech | Meals · 2025-10-27 | Tremfya | $26 |
| Regeneron Healthcare Solutions | Meals · 2025-10-25 | Dupixent | $27 |
| Incyte | Meals · 2025-10-22 | Opzelura | $24 |
| Novartis Pharmaceuticals | Meals · 2025-10-21 | Cosentyx | $25 |
| Abbvie | Meals · 2025-10-16 | Rinvoq | $17 |
| Janssen Biotech | Meals · 2025-10-14 | Tremfya | $22 |
| Novartis Pharmaceuticals | Meals · 2025-10-03 | Rhapsido | $25 |
| Lilly USA | Meals · 2025-09-05 | Taltz | $21 |
| Abbvie | Meals · 2025-09-03 | Rinvoq | $30 |
| Novartis Pharmaceuticals | Meals · 2025-08-18 | Cosentyx | $28 |
| Novartis Pharmaceuticals | Meals · 2025-08-18 | Cosentyx | $28 |
| Lilly USA | Meals · 2025-08-11 | Taltz | $30 |
| Janssen Biotech | Meals · 2025-07-29 | Tremfya | $32 |
| Regeneron Healthcare Solutions | Meals · 2025-07-29 | Dupixent | $12 |
| Ortho Dermatologics a division of Bausch Health US | Meals · 2025-07-28 | Cabtreo | $24 |
| Lilly USA | Meals · 2025-07-21 | Taltz | $30 |
| Genzyme | Meals · 2025-07-16 | Dupixent | $29 |
| Janssen Biotech | Meals · 2025-07-09 | Tremfya | $26 |
| Novartis Pharmaceuticals | Meals · 2025-06-27 | Cosentyx | $29 |
| Janssen Biotech | Meals · 2025-06-20 | Tremfya | $19 |
| Lilly USA | Meals · 2025-06-09 | Taltz | $29 |
| Regeneron Healthcare Solutions | Meals · 2025-06-05 | Dupixent | $27 |
| Lilly USA | Meals · 2025-05-29 | Taltz | $25 |
| Regeneron Healthcare Solutions | Meals · 2025-05-22 | Dupixent | $19 |
| Lilly USA | Meals · 2025-04-18 | Taltz | $28 |
| Janssen Biotech | Meals · 2025-04-02 | Tremfya | $24 |
| Janssen Biotech | Meals · 2025-03-28 | Tremfya | $10 |
| Janssen Biotech | Meals · 2025-03-28 | Tremfya | $25 |
| Regeneron Healthcare Solutions | Meals · 2025-03-11 | Dupixent | $26 |
| Genzyme | Meals · 2025-03-05 | Dupixent | $34 |
See earlier years (2024)
2024: $132
| Regeneron Healthcare Solutions | Libtayo | $74 | 2 payments
|
| Sun Pharmaceutical Industries | Winlevi | $30 | 2 payments
|
| Deciphera Pharmaceuticals | Qinlock | $28 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 99.1 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1629509229
- Licence
- CA A172346California A172346: Current · expires 2027-04-30
- Trained
- University of California, San Diego School of Medicine, 2017
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207ND0101X (207ND0101X); Federal specialty code 207N00000X (207N00000X)
- Mailing address
- Po Box 276950, Sacramento, CA, 95827
- NPI first listed
- 2017-03-24
- NPI last updated
- 2025-02-25
- NPI record certified
- 2025-02-25
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 301 W Huntington Dr Ste 400, Arcadia, CA, 91007 · 2460 N Ponderosa Dr Ste A117, Camarillo, CA, 93010 · 1500 Duarte Rd, Duarte, CA, 91010
This office lists an electronic records connection.